期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

水蛭素对凝血过程中凝血酶活化的纤溶抑制物的影响 被引量：2

原文传递
导出
摘要 凝血酶活化的纤溶抑制物（TAFI）是一种最近被证实的血浆中的纤溶抑制物，在凝血和纤溶方面具有重要的作用。van Tilburg等的研究显示，TAFI升高可使静脉血栓的危险性轻度增加。Hori等发现2型糖尿病患者TAFI血浆浓度和活性显著高于健康对照组，肥胖患者TAFI浓度和活性显著高于非肥胖的糖尿病患者和非肥胖的健康个体。
作者 黎明 张荣军 曹国宪 孙钧铭 金坚
机构地区 无锡 江苏原子医学研究所 无锡市第三人民医院
出处 《中华血液学杂志》 CAS CSCD 北大核心 2006年第3期201-203,共3页 Chinese Journal of Hematology
基金 江苏省自然科学基金(BK2001165)
关键词 纤溶抑制物 凝血过程 酶活化 2型糖尿病患者 水蛭素 TAFI 血浆浓度 肥胖患者 健康对照组 静脉血栓
分类号 R285 [医药卫生—中药学]
  • 相关文献

参考文献9

  • 1Bouma BN,Marx PF,Mosnier LO,et al.Thrombin-activatable fibrinolysis inhibitor (TAFI,plasma procarboxypeptidase B,procarboxypeptidase R,procarboxypeptidase U).Thromb Res,2001,101:329 -354.
  • 2van Tilburg NH,Rosendaal FR,Bertina RM.Thrombin activatable fibrinolysis inhibitor and vein the risk for deep thrombosis.Blood,2000,95:2855-2859.
  • 3Hori Y,Gabazza EC,Yano Y,et al.Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.J Clin Endocrinol Metab,2002,87:660-665.
  • 4Colucci M,Pentimone A,Binetti BM,et al.Effect of heparin on TAFI-dependent inhibition of fibrinolysis:relative importance of TAFIa generated by clot-bound and fluid phase thrombin.Thromb Haemost,2002,88:282-287.
  • 5黄震华.新型抗凝和抗血小板新药——重组水蛭素[J].中国新药与临床杂志,2003,22(5):309-312. 被引量：28
  • 6Mosnier LO,yon dem Borne PAK,Meijers JC,et al.Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.Thromb Haemost,1998,80:829-835.
  • 7Minnema MC,Friederich PW,Levi M,et al.Enhancement of rabbit jugular vein thrombosis by neutralization of factor .J Clin Invest,1998,101:10-14.
  • 8Klement P,Liao P,Bajzar L.A novel approach to arterial thrombolysis.Blood,1999,94:2735-2743.
  • 9Nagashima M,Werner M,Wang M,et al.An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombosis model.Thromb Res,2000,98:333-342.

二级参考文献15

  • 1Global Use of Strategies to Open Occluded Coronary Arteries(GUSTO) lib Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes[J]. N Engl J Med,1996,335(ll):775-782.
  • 2NEUHAUS KL, MOLHOEK GP, ZEYMER U, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: resuits of the HIT-4 trial[J]. J Am Coll Cardiol, 1999,34(4) :966-973.
  • 3NEUHAUS KL, von ESSEN R, TEBBE U, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis(HIT-Ⅲ ) study. A study of the arbeitsgemeinschaft leitender kardiologischer krankenhausarzte(ALKK) [J]. Circulation, 1994,90(4) : 1638-1642.
  • 4RUPPRECHT HJ, TERRES W, OZBEK C, et al. Recombinant hirudin(HBW 023) prevent troponin T release after coronary angioplasty in patients with unstable angina[ J ]. J Am Coll Cardiol,1995,26(7) : 1637-1642.
  • 5SERRUYS PW, HERRMAN J-PR, SIMON R, et al. For the helvetica investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty[J]. N Engl J Med, 1995,333(12) :757-763.
  • 6WARKENTIN TE, LEVINE MN, HIRSH J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin [ J ]. N Engl J Med,1995,332 (20) : 1330-1335.
  • 7GREINACHER A, VOLPEL H, JANSSENS U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: a prospective study[ J ]. Circulation, 1999,99(1) :73-80.
  • 8GREINACHER A, JANSSENS U, BERG G, et al. Lepirudin(recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia [ J ]. Circulation, 1999,100(6) :587-593.
  • 9ERIKSSON BI, WILLE-JORGENSEN P, KALEPO P, et al. A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement[J]. N Enqgl J Med, 1997,337(19) : 1329-1335.
  • 10METZ BK, WHITE HD, GRANGER CB, et al. Randomized comparison of direct thrombin inhibition versus heparin in conj unction with fibrinolytic therapy for acute myocardial infarction:results from the GUSTO-lib trial[ J ]. J Am Coll Cardiol, 1998,31(7) : 1493-1498.

共引文献27

同被引文献44

引证文献2

二级引证文献8

中华血液学杂志
2006年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部